Evidence map›Paper›PMID 39885506›Full record

ArticleBMC medical genomics2025

A dedicated caller for DUX4 rearrangements from whole-genome sequencing data.

Pascal Grobecker, Stefano Berri, John F Peden, Kai-Jie Chow, Claire Fielding, Ivana Armogida, Helen Northen, David J McBride, Peter J Campbell, Jennifer Becq and 6 more

Abstract read
In one paragraph

Article in BMC medical genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Observational
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Pascal GrobeckerIllumina Cambridge Ltd., Granta Park, Great Abington, Cambridge, UK.
Stefano BerriIllumina Cambridge Ltd., Granta Park, Great Abington, Cambridge, UK.
John F PedenGenpax Ltd, Office 4.05, 53, 64 Chancery Ln, London, UK.
Kai-Jie ChowIllumina Cambridge Ltd., Granta Park, Great Abington, Cambridge, UK.
Claire FieldingIllumina Cambridge Ltd., Granta Park, Great Abington, Cambridge, UK.
Ivana ArmogidaIllumina Cambridge Ltd., Granta Park, Great Abington, Cambridge, UK.
Helen NorthenIllumina Cambridge Ltd., Granta Park, Great Abington, Cambridge, UK.
David J McBrideIllumina Cambridge Ltd., Granta Park, Great Abington, Cambridge, UK.
Peter J CampbellIllumina Cambridge Ltd., Granta Park, Great Abington, Cambridge, UK.
Jennifer BecqIllumina Cambridge Ltd., Granta Park, Great Abington, Cambridge, UK.
Sarra L RyanLeukaemia Research Cytogenetics Group, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University Centre for Cancer, Newcastle upon Tyne, UK.
David R BentleyIllumina Cambridge Ltd., Granta Park, Great Abington, Cambridge, UK.
Christine J HarrisonLeukaemia Research Cytogenetics Group, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University Centre for Cancer, Newcastle upon Tyne, UK.
Anthony V MoormanLeukaemia Research Cytogenetics Group, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University Centre for Cancer, Newcastle upon Tyne, UK.
Mark T RossIllumina Cambridge Ltd., Granta Park, Great Abington, Cambridge, UK. mross@illumina.com.
Martina MijuskovicIllumina Cambridge Ltd., Granta Park, Great Abington, Cambridge, UK. mmijuskovic@illumina.com.

Funding

Blood Cancer UK 15036Cancer Research UK C60802/A27193
6 · The paper itself

Abstract

Rearrangements involving the DUX4 gene (DUX4-r) define a subtype of paediatric and adult acute lymphoblastic leukaemia (ALL) with a favourable outcome. Currently, there is no 'standard of care' diagnostic method for their confident identification. Here, we present an open-source software tool designed to detect DUX4-r from short-read, whole-genome sequencing (WGS) data. Evaluation on a cohort of 210 paediatric ALL cases showed that our method detects all known, as well as previously unidentified, cases of IGH::DUX4 and rearrangements with other partner genes. These findings demonstrate the possibility of robustly detecting DUX4-r using WGS in the routine clinical setting.

Indexed as

Gene RearrangementHomeodomain ProteinsPrecursor Cell Lymphoblastic Leukemia-LymphomaSoftwareWhole Genome SequencingChildHumansDUX4L1 protein, humanHomeodomain ProteinsAcute lymphoblastic leukaemiaALLDUX4IGH:DUX4IGH enhancer hijackingWhole-genome sequencing

Identifiers

PMID39885506
PMCPMC11783778

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.